Cerus Corporation

    Jurisdiction
    United States
    LEI
    254900BIEY9XIDA04Q21
    ISIN
    US1570851014 (CERS)
    Sectors
    1. Healthcare
    2. Medical - Devices

    Scores

    InsiderPie Expert Score
    51 / 100
    Even with peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    6 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    5 / 7

    Profile

    Cerus Corporation operates as a biomedical products company. Read full profile

    Fundamentals

    Net revenue
    €164.20M
    Gross margin
    56.1%
    EBIT
    -€9.97M
    EBIT margin
    -6.1%
    Net income
    -€16.10M
    Net margin
    -9.8%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €213.24M +29.9% -€11.17M -30.7%
    €239.47M +12.3% €2.00M -118.0%
    N/A N/A

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Gregory Dean A. N/A +25K $1.25 +$31.25K

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Cathie Wood 21M $28.71M -160K Sell
    Peter Brown 1.4M $1.90M +954K Buy

    Earnings Calls

    Latest earnings call: May 2, 2024 (Q1 2024)

    Add to watchlist

    Notifications